(+)-schisandrin B multiple interactions EXP 6480464 schizandrin B inhibits the reaction [Carbon Tetrachloride results in decreased expression of MYLK mRNA] CTD PMID:31150632 (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in increased expression of MYLK mRNA CTD PMID:25729387 (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE increases expression EXP 6480464 Topotecan results in increased expression of MYLK mRNA CTD PMID:25729387 1,2-dimethylhydrazine multiple interactions EXP 6480464 [APC protein affects the susceptibility to 1, 2-Dimethylhydrazine] which results in increased expression of MYLK mRNA CTD PMID:27840820 1,3-dinitrobenzene increases expression EXP 6480464 3-dinitrobenzene results in increased expression of MYLK mRNA CTD PMID:24140754 1-octadec-9-enoylglycero-3-phosphate affects response to substance ISO RGD:1322095 6480464 MYLK protein affects the susceptibility to lysophosphatidic acid CTD PMID:10640419 17alpha-ethynylestradiol decreases expression EXP 6480464 Ethinyl Estradiol results in decreased expression of MYLK mRNA CTD PMID:17557909 17beta-estradiol multiple interactions ISO RGD:1322095 6480464 [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MYLK mRNA more ... CTD PMID:17404688 more ... 17beta-estradiol multiple interactions ISO RGD:1616651 6480464 Estradiol inhibits the reaction [Lipopolysaccharides results in increased expression of MYLK mRNA] CTD PMID:16977382 2,2',4,4'-Tetrabromodiphenyl ether increases expression ISO RGD:1322095 6480464 2 more ... CTD PMID:19095052 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:1616651 6480464 Tetrachlorodibenzodioxin affects the expression of MYLK mRNA CTD PMID:21570461 2,3,7,8-tetrachlorodibenzodioxine affects expression EXP 6480464 Tetrachlorodibenzodioxin affects the expression of MYLK mRNA CTD PMID:22298810 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione increases expression ISO RGD:1616651 6480464 Thalidomide results in increased expression of MYLK mRNA CTD PMID:26217789 2-methoxyethanol increases expression EXP 6480464 methyl cellosolve metabolite results in increased expression of MYLK protein CTD PMID:11794376 3-methylcholanthrene multiple interactions ISO RGD:1616651 6480464 [Methylcholanthrene co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of MYLK mRNA CTD PMID:23519560 4-hydroxynon-2-enal decreases expression ISO RGD:1322095 6480464 4-hydroxy-2-nonenal results in decreased expression of MYLK mRNA CTD PMID:12419474 4-hydroxyphenyl retinamide increases expression ISO RGD:1616651 6480464 Fenretinide results in increased expression of MYLK mRNA CTD PMID:28973697 6-propyl-2-thiouracil affects expression EXP 6480464 Propylthiouracil affects the expression of MYLK mRNA CTD PMID:24780913 actinomycin D multiple interactions ISO RGD:1322095 6480464 Dactinomycin inhibits the reaction [TNF protein results in increased expression of MYLK mRNA], Dactinomycin inhibits the reaction [TNF protein results in increased expression of MYLK protein] CTD PMID:15701621 aflatoxin B1 decreases expression ISO RGD:1322095 6480464 Aflatoxin B1 results in decreased expression of MYLK mRNA CTD PMID:21632981 more ... aflatoxin B1 increases methylation ISO RGD:1322095 6480464 Aflatoxin B1 results in increased methylation of MYLK exon, Aflatoxin B1 results in increased methylation of MYLK gene CTD PMID:27153756 , PMID:30157460 aflatoxin B1 affects expression ISO RGD:1322095 6480464 Aflatoxin B1 affects the expression of MYLK protein CTD PMID:20106945 aldehydo-D-glucose increases uptake ISO RGD:1616651 6480464 MYLK protein results in increased uptake of Glucose CTD PMID:18773891 aldehydo-D-glucose multiple interactions ISO RGD:1616651 6480464 ML 7 inhibits the reaction [MYLK protein results in increased uptake of Glucose], ML 9 inhibits the reaction [MYLK protein results in increased uptake of Glucose] CTD PMID:18773891 all-trans-retinoic acid decreases expression ISO RGD:1322095 6480464 Tretinoin results in decreased expression of MYLK mRNA CTD PMID:21934132 antirheumatic drug increases expression ISO RGD:1322095 6480464 Antirheumatic Agents results in increased expression of MYLK mRNA CTD PMID:24449571 belinostat decreases expression ISO RGD:1322095 6480464 belinostat results in decreased expression of MYLK mRNA CTD PMID:26272509 benzo[a]pyrene decreases expression ISO RGD:1322095 6480464 Benzo(a)pyrene results in decreased expression of MYLK mRNA CTD PMID:20106945 more ... Benzo[k]fluoranthene decreases expression ISO RGD:1322095 6480464 benzo(k)fluoranthene results in decreased expression of MYLK mRNA CTD PMID:21635667 bis(2-ethylhexyl) phthalate multiple interactions ISO RGD:1616651 6480464 PPARA protein promotes the reaction [Diethylhexyl Phthalate results in decreased expression of MYLK mRNA] CTD PMID:19850644 bis(2-ethylhexyl) phthalate decreases expression ISO RGD:1322095 6480464 Diethylhexyl Phthalate results in decreased expression of MYLK protein CTD PMID:31163220 bis(2-ethylhexyl) phthalate decreases expression ISO RGD:1616651 6480464 Diethylhexyl Phthalate results in decreased expression of MYLK mRNA CTD PMID:19850644 bisphenol A affects expression EXP 6480464 bisphenol A affects the expression of MYLK mRNA CTD PMID:25181051 bucladesine multiple interactions ISO RGD:1322095 6480464 [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MYLK mRNA CTD PMID:20823114 butanal decreases expression ISO RGD:1322095 6480464 butyraldehyde results in decreased expression of MYLK mRNA CTD PMID:26079696 calcitriol multiple interactions ISO RGD:1322095 6480464 [Testosterone co-treated with Calcitriol] results in increased expression of MYLK mRNA CTD PMID:21592394 calcitriol increases expression ISO RGD:1322095 6480464 Calcitriol results in increased expression of MYLK mRNA CTD PMID:21592394 calcium atom increases activity ISO RGD:1322095 6480464 Calcium deficiency results in increased activity of MYLK protein, Calcium results in increased activity of MYLK protein CTD PMID:10640419 , PMID:11054866 calcium atom multiple interactions EXP 6480464 [[Calcium results in increased activity of MYLK protein] which results in increased phosphorylation of MYL9 protein] which results in decreased secretion of REN protein CTD PMID:9618396 calcium atom multiple interactions ISO RGD:1322095 6480464 ML 7 inhibits the reaction [Calcium deficiency results in increased activity of MYLK protein] CTD PMID:11054866 calcium(0) increases activity ISO RGD:1322095 6480464 Calcium deficiency results in increased activity of MYLK protein, Calcium results in increased activity of MYLK protein CTD PMID:10640419 , PMID:11054866 calcium(0) multiple interactions EXP 6480464 [[Calcium results in increased activity of MYLK protein] which results in increased phosphorylation of MYL9 protein] which results in decreased secretion of REN protein CTD PMID:9618396 calcium(0) multiple interactions ISO RGD:1322095 6480464 ML 7 inhibits the reaction [Calcium deficiency results in increased activity of MYLK protein] CTD PMID:11054866 carbachol affects response to substance EXP 6480464 MYLK protein affects the susceptibility to Carbachol CTD PMID:17272850 carbamazepine affects expression ISO RGD:1322095 6480464 Carbamazepine affects the expression of MYLK mRNA CTD PMID:25979313 carbon nanotube decreases expression ISO RGD:1616651 6480464 Nanotubes, Carbon analog results in decreased expression of MYLK mRNA, Nanotubes, Carbon results in decreased expression of MYLK mRNA CTD PMID:25620056 chrysene increases expression ISO RGD:1616651 6480464 chrysene results in increased expression of MYLK mRNA CTD PMID:26377693 cisplatin multiple interactions ISO RGD:1322095 6480464 [Cisplatin co-treated with jinfukang] results in increased expression of MYLK mRNA CTD PMID:27392435 cisplatin increases expression ISO RGD:1322095 6480464 Cisplatin results in increased expression of MYLK mRNA CTD PMID:27392435 cobalt dichloride decreases expression EXP 6480464 cobaltous chloride results in decreased expression of MYLK mRNA, cobaltous chloride results in decreased expression of MYLK protein CTD PMID:24386269 copper atom multiple interactions ISO RGD:1322095 6480464 [Disulfiram binds to Copper] which results in increased expression of MYLK mRNA, [NSC 689534 binds to Copper] which results in increased expression of MYLK mRNA CTD PMID:20971185 , PMID:24690739 copper(0) multiple interactions ISO RGD:1322095 6480464 [Disulfiram binds to Copper] which results in increased expression of MYLK mRNA, [NSC 689534 binds to Copper] which results in increased expression of MYLK mRNA CTD PMID:20971185 , PMID:24690739 copper(2+) multiple interactions ISO RGD:1322095 6480464 [Disulfiram binds to Copper] which results in increased expression of MYLK mRNA, [NSC 689534 binds to Copper] which results in increased expression of MYLK mRNA CTD PMID:20971185 , PMID:24690739 crocidolite asbestos decreases expression ISO RGD:1322095 6480464 Asbestos, Crocidolite results in decreased expression of MYLK mRNA CTD PMID:25351596 curcumin increases expression ISO RGD:1322095 6480464 Curcumin results in increased expression of MYLK mRNA CTD PMID:21594647 cycloheximide multiple interactions ISO RGD:1322095 6480464 Cycloheximide inhibits the reaction [TNF protein results in increased expression of MYLK protein] CTD PMID:15701621 cyclosporin A decreases expression ISO RGD:1322095 6480464 Cyclosporine results in decreased expression of MYLK mRNA CTD PMID:20106945 , PMID:27989131 cyclosporin A affects expression ISO RGD:1322095 6480464 Cyclosporine affects the expression of MYLK mRNA CTD PMID:25562108 cyclosporin A decreases expression ISO RGD:1616651 6480464 Cyclosporine results in decreased expression of MYLK mRNA CTD PMID:19770486 D-glucose multiple interactions ISO RGD:1616651 6480464 ML 7 inhibits the reaction [MYLK protein results in increased uptake of Glucose], ML 9 inhibits the reaction [MYLK protein results in increased uptake of Glucose] CTD PMID:18773891 D-glucose increases uptake ISO RGD:1616651 6480464 MYLK protein results in increased uptake of Glucose CTD PMID:18773891 dexamethasone increases expression ISO RGD:1322095 6480464 Dexamethasone results in increased expression of MYLK mRNA CTD PMID:25047013 dimethylarsinous acid decreases expression ISO RGD:1322095 6480464 dimethylarsinous acid results in decreased expression of MYLK mRNA CTD PMID:16507463 dioxygen multiple interactions ISO RGD:1616651 6480464 [NFE2L2 protein affects the susceptibility to Oxygen] which affects the expression of MYLK mRNA CTD PMID:30529165 disulfiram multiple interactions ISO RGD:1322095 6480464 [Disulfiram binds to Copper] which results in increased expression of MYLK mRNA CTD PMID:24690739 diuron decreases expression EXP 6480464 Diuron results in decreased expression of MYLK mRNA CTD PMID:25152437 diuron increases expression EXP 6480464 Diuron results in increased expression of MYLK mRNA CTD PMID:21551480 dorsomorphin multiple interactions ISO RGD:1322095 6480464 [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 doxorubicin decreases expression EXP 6480464 Doxorubicin results in decreased expression of MYLK protein CTD PMID:12717111 doxorubicin decreases expression ISO RGD:1322095 6480464 Doxorubicin results in decreased expression of MYLK mRNA CTD PMID:29803840 emodin increases activity EXP 6480464 Emodin results in increased activity of MYLK protein CTD PMID:15133857 endosulfan decreases expression EXP 6480464 Endosulfan results in decreased expression of MYLK mRNA CTD PMID:29391264 entinostat decreases expression ISO RGD:1322095 6480464 entinostat results in decreased expression of MYLK mRNA CTD PMID:26272509 entinostat multiple interactions ISO RGD:1322095 6480464 [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYLK mRNA CTD PMID:27188386 ethanol increases expression ISO RGD:1322095 6480464 Ethanol results in increased expression of MYLK mRNA CTD PMID:25226407 ethanol multiple interactions ISO RGD:1322095 6480464 ML 7 inhibits the reaction [Ethanol results in increased activity of MYLK protein] CTD PMID:10198341 ethanol increases activity ISO RGD:1322095 6480464 Ethanol results in increased activity of MYLK protein CTD PMID:10198341 fenofibrate decreases expression ISO RGD:1322095 6480464 Fenofibrate results in decreased expression of MYLK mRNA CTD PMID:25572481 furan decreases expression EXP 6480464 furan results in decreased expression of MYLK mRNA CTD PMID:25539665 genistein decreases expression ISO RGD:1322095 6480464 Genistein results in decreased expression of MYLK mRNA CTD PMID:22228119 ginsenoside Re affects expression EXP 6480464 ginsenoside Re affects the expression of MYLK mRNA, ginsenoside Re affects the expression of MYLK protein CTD PMID:24658813 glafenine decreases expression EXP 6480464 Glafenine results in decreased expression of MYLK mRNA CTD PMID:24136188 glucose multiple interactions ISO RGD:1616651 6480464 ML 7 inhibits the reaction [MYLK protein results in increased uptake of Glucose], ML 9 inhibits the reaction [MYLK protein results in increased uptake of Glucose] CTD PMID:18773891 glucose increases uptake ISO RGD:1616651 6480464 MYLK protein results in increased uptake of Glucose CTD PMID:18773891 hydrogen peroxide affects expression ISO RGD:1322095 6480464 Hydrogen Peroxide affects the expression of MYLK mRNA CTD PMID:23410634 Indeno[1,2,3-cd]pyrene decreases expression ISO RGD:1322095 6480464 indeno(1 more ... CTD PMID:21635667 indometacin increases expression ISO RGD:1322095 6480464 Indomethacin results in increased expression of MYLK mRNA CTD PMID:24737281 lipopolysaccharide multiple interactions ISO RGD:1616651 6480464 Estradiol inhibits the reaction [Lipopolysaccharides results in increased expression of MYLK mRNA] more ... CTD PMID:16977382 , PMID:19374788 lipopolysaccharide affects response to substance EXP 6480464 MYLK protein affects the susceptibility to Lipopolysaccharides CTD PMID:16192642 lipopolysaccharide increases expression ISO RGD:1616651 6480464 Lipopolysaccharides results in increased expression of MYLK mRNA, Lipopolysaccharides results in increased expression of MYLK protein CTD PMID:16977382 , PMID:19374788 losartan multiple interactions EXP 6480464 Losartan inhibits the reaction [AGT protein results in increased expression of MYLK protein] CTD PMID:18511912 medroxyprogesterone acetate multiple interactions ISO RGD:1322095 6480464 [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MYLK mRNA CTD PMID:20823114 menadione affects expression ISO RGD:1322095 6480464 Vitamin K 3 affects the expression of MYLK mRNA CTD PMID:23410634 mercury dibromide decreases expression ISO RGD:1322095 6480464 mercuric bromide results in decreased expression of MYLK mRNA CTD PMID:26272509 mercury dibromide multiple interactions ISO RGD:1322095 6480464 [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYLK mRNA CTD PMID:27188386 methamphetamine affects expression EXP 6480464 Methamphetamine affects the expression of MYLK mRNA CTD PMID:19564919 methamphetamine multiple interactions EXP 6480464 [Methamphetamine co-treated with SCH 23390] affects the expression of MYLK mRNA CTD PMID:19564919 methamphetamine increases expression ISO RGD:1616651 6480464 Methamphetamine results in increased expression of MYLK mRNA CTD PMID:26307267 methapyrilene decreases expression EXP 6480464 Methapyrilene results in decreased expression of MYLK mRNA CTD PMID:30467583 methoxyacetic acid increases expression EXP 6480464 methoxyacetic acid results in increased expression of MYLK protein CTD PMID:11794376 methylmercury chloride decreases expression ISO RGD:1322095 6480464 methylmercuric chloride results in decreased expression of MYLK mRNA CTD PMID:28001369 ML-7 decreases activity ISO RGD:1322095 6480464 [ML 7 results in decreased activity of MYLK protein] which results in decreased activity of F2 protein, ML 7 results in decreased activity of MYLK protein CTD PMID:10733514 more ... ML-7 multiple interactions EXP 6480464 [[ML 7 results in decreased activity of MYLK protein] which results in decreased phosphorylation of MYL9 protein] which results in increased secretion of REN protein, [ML 7 results in decreased activity of MYLK protein] which results in decreased phosphorylation of MYL9 protein CTD PMID:18835913 , PMID:9618396 ML-7 decreases activity ISO RGD:1616651 6480464 ML 7 results in decreased activity of MYLK protein CTD PMID:19943851 ML-7 multiple interactions ISO RGD:1322095 6480464 [ML 7 results in decreased activity of MYLK protein] which results in decreased phosphorylation of MYL9 protein more ... CTD PMID:10198341 more ... ML-7 multiple interactions ISO RGD:1616651 6480464 ML 7 inhibits the reaction [Lipopolysaccharides results in increased expression of MYLK mRNA] more ... CTD PMID:18773891 , PMID:19374788 ML-7 decreases activity EXP 6480464 ML 7 results in decreased activity of MYLK protein CTD PMID:17541957 N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal multiple interactions ISO RGD:1616651 6480464 [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of MYLK mRNA CTD PMID:25566086 N-methyl-4-phenylpyridinium decreases expression EXP 6480464 1-Methyl-4-phenylpyridinium results in decreased expression of MYLK mRNA CTD PMID:28801915 N-methyl-N'-nitro-N-nitrosoguanidine decreases expression ISO RGD:1322095 6480464 Methylnitronitrosoguanidine results in decreased expression of MYLK mRNA CTD PMID:12634122 nickel atom increases expression ISO RGD:1616651 6480464 Nickel results in increased expression of MYLK mRNA CTD PMID:18922574 nickel atom decreases expression ISO RGD:1322095 6480464 Nickel results in decreased expression of MYLK mRNA CTD PMID:24768652 , PMID:25583101 ouabain decreases expression ISO RGD:1322095 6480464 Ouabain results in decreased expression of MYLK mRNA CTD PMID:28795476 oxaliplatin multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in increased expression of MYLK mRNA CTD PMID:25729387 p-chloromercuribenzoic acid decreases expression ISO RGD:1322095 6480464 p-Chloromercuribenzoic Acid results in decreased expression of MYLK mRNA CTD PMID:26272509 p-chloromercuribenzoic acid multiple interactions ISO RGD:1322095 6480464 [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYLK mRNA CTD PMID:27188386 panobinostat multiple interactions ISO RGD:1322095 6480464 [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYLK mRNA CTD PMID:27188386 panobinostat decreases expression ISO RGD:1322095 6480464 panobinostat results in decreased expression of MYLK mRNA CTD PMID:26272509 paracetamol decreases expression ISO RGD:1322095 6480464 Acetaminophen results in decreased expression of MYLK mRNA CTD PMID:21420995 more ... phenylmercury acetate decreases expression ISO RGD:1322095 6480464 Phenylmercuric Acetate results in decreased expression of MYLK mRNA CTD PMID:26272509 phenylmercury acetate multiple interactions ISO RGD:1322095 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYLK mRNA CTD PMID:27188386 phorbol 13-acetate 12-myristate multiple interactions ISO RGD:1616651 6480464 [Methylcholanthrene co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of MYLK mRNA CTD PMID:23519560 pioglitazone multiple interactions ISO RGD:1616651 6480464 [N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of MYLK mRNA CTD PMID:27935865 pirinixic acid multiple interactions ISO RGD:1616651 6480464 [pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of MYLK mRNA CTD PMID:19710929 pirinixic acid decreases expression ISO RGD:1616651 6480464 pirinixic acid results in decreased expression of MYLK mRNA CTD PMID:23811191 progesterone multiple interactions ISO RGD:1322095 6480464 [Estradiol co-treated with Progesterone] results in decreased expression of MYLK mRNA, [Progesterone co-treated with Estradiol] results in decreased expression of MYLK mRNA CTD PMID:17404688 , PMID:20660070 propiconazole decreases expression ISO RGD:1616651 6480464 propiconazole results in decreased expression of MYLK mRNA CTD PMID:21278054 quercetin decreases expression ISO RGD:1322095 6480464 Quercetin results in decreased expression of MYLK mRNA CTD PMID:21632981 SB 431542 multiple interactions ISO RGD:1322095 6480464 [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 SCH 23390 decreases expression EXP 6480464 SCH 23390 results in decreased expression of MYLK mRNA CTD PMID:19564919 SCH 23390 multiple interactions EXP 6480464 [Methamphetamine co-treated with SCH 23390] affects the expression of MYLK mRNA CTD PMID:19564919 silicon dioxide decreases expression ISO RGD:1322095 6480464 Silicon Dioxide results in decreased expression of MYLK mRNA CTD PMID:25351596 sirolimus multiple interactions ISO RGD:1322095 6480464 Sirolimus inhibits the reaction [TP73 protein results in increased expression of MYLK mRNA] CTD PMID:21245298 sodium arsenate increases expression ISO RGD:1616651 6480464 sodium arsenate results in increased expression of MYLK mRNA CTD PMID:21795629 sodium arsenite decreases expression ISO RGD:1322095 6480464 sodium arsenite results in decreased expression of MYLK mRNA CTD PMID:16507463 sodium arsenite decreases expression EXP 6480464 sodium arsenite results in decreased expression of MYLK protein CTD PMID:29459688 sodium dichromate affects expression EXP 6480464 sodium bichromate affects the expression of MYLK mRNA CTD PMID:22110744 sodium fluoride decreases expression ISO RGD:1616651 6480464 Sodium Fluoride results in decreased expression of MYLK protein CTD PMID:28918527 succimer multiple interactions ISO RGD:1616651 6480464 [Succimer co-treated with Magnetite Nanoparticles] results in increased expression of MYLK mRNA CTD PMID:26378955 tert-butyl hydroperoxide decreases expression ISO RGD:1322095 6480464 tert-Butylhydroperoxide results in decreased expression of MYLK mRNA CTD PMID:12419474 tert-butyl hydroperoxide affects expression ISO RGD:1322095 6480464 tert-Butylhydroperoxide affects the expression of MYLK mRNA CTD PMID:23410634 testosterone multiple interactions ISO RGD:1322095 6480464 [Testosterone co-treated with Calcitriol] results in increased expression of MYLK mRNA CTD PMID:21592394 testosterone increases expression ISO RGD:1322095 6480464 Testosterone results in increased expression of MYLK mRNA CTD PMID:21592394 tetrachloromethane decreases expression EXP 6480464 Carbon Tetrachloride results in decreased expression of MYLK mRNA CTD PMID:31150632 tetrachloromethane multiple interactions EXP 6480464 schizandrin B inhibits the reaction [Carbon Tetrachloride results in decreased expression of MYLK mRNA] CTD PMID:31150632 thalidomide increases expression ISO RGD:1616651 6480464 Thalidomide results in increased expression of MYLK mRNA CTD PMID:26217789 thioacetamide decreases expression EXP 6480464 Thioacetamide results in decreased expression of MYLK mRNA CTD PMID:23411599 titanium dioxide increases expression ISO RGD:1616651 6480464 titanium dioxide results in increased expression of MYLK mRNA CTD PMID:23557971 topotecan multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in increased expression of MYLK mRNA CTD PMID:25729387 topotecan increases expression EXP 6480464 Topotecan results in increased expression of MYLK mRNA CTD PMID:25729387 trichostatin A increases expression ISO RGD:1322095 6480464 trichostatin A results in increased expression of MYLK mRNA CTD PMID:24935251 , PMID:26238599 trichostatin A multiple interactions ISO RGD:1322095 6480464 [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYLK mRNA CTD PMID:27188386 trichostatin A decreases expression ISO RGD:1322095 6480464 trichostatin A results in decreased expression of MYLK mRNA CTD PMID:24935251 , PMID:26272509 urethane decreases expression ISO RGD:1322095 6480464 Urethane results in decreased expression of MYLK mRNA CTD PMID:28818685 valproic acid affects expression ISO RGD:1322095 6480464 Valproic Acid affects the expression of MYLK mRNA CTD PMID:25979313 valproic acid multiple interactions ISO RGD:1322095 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYLK mRNA CTD PMID:27188386 valproic acid decreases expression ISO RGD:1322095 6480464 Valproic Acid results in decreased expression of MYLK mRNA CTD PMID:23179753 more ... valproic acid increases expression ISO RGD:1322095 6480464 Valproic Acid results in increased expression of MYLK mRNA CTD PMID:23179753 more ... vasopressin affects response to substance EXP 6480464 MYLK protein affects the susceptibility to Vasopressins CTD PMID:15347643 vinclozolin affects expression EXP 6480464 vinclozolin affects the expression of MYLK mRNA CTD PMID:19015723 vorinostat increases expression ISO RGD:1322095 6480464 vorinostat results in increased expression of MYLK mRNA CTD PMID:26238599
Gene-Chemical Interaction Annotations
